This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Sagopilone
DrugBank Accession Number
DB12391
Background

Sagopilone has been used in trials studying the treatment of Melanoma, Neoplasms, CNS Disease, Breast Cancer, and Breast Neoplasms, among others. It is a so-called fully synthetic epothilone and is the first such compound to be in clinical development to combat several forms of cancer. Epothilones are 16-member ring macrolides with antimicrotubule activity that share a similar mechanism of action to the taxanes but have demonstrated potent antiproliferative activity in several different multidrug-resistant and paclitaxel-resistant tumor cell lines in vitro and in vivo.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 543.72
Monoisotopic: 543.265459218
Chemical Formula
C30H41NO6S
Synonyms
  • Sagopilone
External IDs
  • BAY86-5302
  • DE-03757
  • ZK 219477
  • ZK-219477
  • ZK-EPO

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Sagopilone is a highly potent, fully synthetic epothilone that was specifically designed to be safer and more effective than other chemotherapy drugs like paclitaxel and other epothilones for the treatment of solid tumor cancers. In early phase studies, Sagopilone appears to have greater antitumor activity relative to other epothilones, and appears to cross the blood-brain barrier which may help to treat brain tumors or metastases.

Mechanism of action

Epothilones are a new class of cytotoxic agents that induce tubulin polymerization. Sagopilone, the only fully synthetic, third-generation analogue of epothilone B, is a highly potent tubulin stabilizer that has shown substantial preclinical antitumor activity, including against taxane-resistant models.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Sagopilone.
AcalabrutinibThe metabolism of Acalabrutinib can be decreased when combined with Sagopilone.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Sagopilone.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Sagopilone.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Sagopilone.
AlectinibThe metabolism of Alectinib can be decreased when combined with Sagopilone.
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Sagopilone.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Sagopilone.
AlpelisibThe metabolism of Alpelisib can be decreased when combined with Sagopilone.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Sagopilone.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as macrolides and analogues. These are organic compounds containing a lactone ring of at least twelve members.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Macrolides and analogues
Sub Class
Not Available
Direct Parent
Macrolides and analogues
Alternative Parents
Benzothiazoles / Benzenoids / Thiazoles / Heteroaromatic compounds / Secondary alcohols / Lactones / Carboxylic acid esters / Cyclic ketones / Oxacyclic compounds / Azacyclic compounds
show 7 more
Substituents
1,3-benzothiazole / Alcohol / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Cyclic ketone
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
KY72JU32FO
CAS number
305841-29-6
InChI Key
BFZKMNSQCNVFGM-UCEYFQQTSA-N
InChI
InChI=1S/C30H41NO6S/c1-7-9-20-27(34)17(2)10-8-13-30(6)25(37-30)15-22(19-11-12-23-21(14-19)31-18(3)38-23)36-26(33)16-24(32)29(4,5)28(20)35/h7,11-12,14,17,20,22,24-25,27,32,34H,1,8-10,13,15-16H2,2-6H3/t17-,20+,22-,24-,25-,27-,30+/m0/s1
IUPAC Name
(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-10-(prop-2-en-1-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione
SMILES
C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](CC=C)[C@H]1O)C1=CC=C2SC(C)=NC2=C1

References

General References
  1. Fumoleau P, Coudert B, Isambert N, Ferrant E: Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007 Jul;18 Suppl 5:v9-15. [Article]
  2. Cortes J, Baselga J: Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist. 2007 Mar;12(3):271-80. [Article]
  3. Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, Lichtner RB: Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl. 2006 Dec 4;45(47):7942-8. [Article]
  4. Larkin JM, Kaye SB: Epothilones in the treatment of cancer. Expert Opin Investig Drugs. 2006 Jun;15(6):691-702. [Article]
PubChem Compound
11284169
PubChem Substance
347828638
ChemSpider
9459163
ChEMBL
CHEMBL2304041
ZINC
ZINC000003964449

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentBrain and Central Nervous System Tumors1
2CompletedTreatmentGlioblastoma Multiforme (GBM)1
2CompletedTreatmentMalignant Melanoma of Skin1
2CompletedTreatmentMetastatic Breast Cancer / Neoplasms, Breast1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNeoplasms, Ovarian2
2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentOvarian Cancer / Prostate Cancer1
2CompletedTreatmentProstate Cancer1
2TerminatedTreatmentBreast Cancer / CNS Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0024 mg/mLALOGPS
logP4.42ALOGPS
logP5.1ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)14.08ChemAxon
pKa (Strongest Basic)2.88ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area109.25 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity145.71 m3·mol-1ChemAxon
Polarizability59.69 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]

Drug created at October 20, 2016 22:11 / Updated at February 21, 2021 18:53